Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk (NYSE:NVO)’s marketing application for an oral version of its weight-loss drug Wegovy and will decide in the fourth ...

(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its weight-loss drug Wegovy ... active ingredient semaglutide, is already ...

Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on ...

25 mg oral formulation of Wegovy ® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy ® (semaglutide). The Company is working with Hims & Hers Health, Inc, ...

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be ...

CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Stream NBC 5 for free ...

In a press release, the Danish drugmaker said that from July 1, CVS Caremark, the largest pharmacy benefit manager in the U.S., has agreed to make Wegovy, the preferred GLP-1 medicine, on its ...